NEWSMAX @NEWSMAX
Sobi North America, a unit of Swedish Orphan Biovitrum AB, said on Thursday the U.S. Food and Drug Administration authorized its arthritis drug for treatment of high-risk hospitalized COVID-19 patients. https://t.co/3rUIj5CDe5 — PolitiTweet.org